Ozempic 0.5 Mg 1 Perfilled Pen

Ozempic 0.5 Mg 1 Perfilled Pen

Description:

Ozempic 0.5 mg pre-filled pen is a prescription injectable diabetes medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used once weekly to help improve blood sugar control in adults with type 2 diabetes mellitus, as part of a comprehensive treatment plan that includes diet and exercise. Ozempic belongs to the class of incretin-based therapies and works by enhancing glucose-dependent insulin secretion, reducing inappropriate glucagon release, and slowing gastric emptying, which together help lower blood glucose levels and may support weight reduction. This product is a medication and should only be used under medical supervision.

Indications:

• Management of type 2 diabetes mellitus in adults to improve glycemic control, as an adjunct to diet and exercise.
• May be used as monotherapy when metformin is not tolerated or contraindicated, or in combination with other oral antidiabetic agents or insulin as directed by a physician.
• Helps reduce fasting and postprandial (after-meal) blood glucose levels.
• May assist in weight reduction in patients with type 2 diabetes due to its effect on appetite and caloric intake (only as part of diabetes management and not as a stand-alone weight-loss drug).

Active Ingredients / Key Components:

• Semaglutide – 0.5 mg per dose (glucagon-like peptide-1 (GLP-1) receptor agonist).
• Other excipients: Information on full excipient list and their concentrations is not available in the provided data. Refer to the official package leaflet for complete composition.

Dosage & Administration / How to Use:

• Ozempic is administered as a subcutaneous injection once weekly, on the same day each week, with or without meals.
• Recommended dosing schedule and titration (for example, starting dose and when to increase to 0.5 mg) must be determined by the prescribing physician according to the official prescribing information. This product name specifies the 0.5 mg strength; follow your doctor’s instructions regarding starting and maintenance doses.
• Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of lipodystrophy or skin irritation.
• Use the pre-filled pen exactly as shown in the patient instruction leaflet. Do not share the pen with others, even if the needle is changed.
• If a dose is missed and it is within 5 days of the scheduled dose, administer the dose as soon as possible and then continue with the regular once-weekly schedule. If more than 5 days have passed, skip the missed dose and take the next dose on the regular day. Do not take an extra dose to make up for a missed one. Always follow your doctor’s advice.
• Do not inject intravenously or intramuscularly. For subcutaneous use only.
• Patients switching from other GLP-1 receptor agonists or other antidiabetic therapies should do so only under medical supervision.

Clinical Benefits:

• Helps significantly lower blood glucose levels in adults with type 2 diabetes when used with diet and exercise.
• Enhances glucose-dependent insulin secretion and reduces inappropriate glucagon secretion, supporting better glycemic control.
• Slows gastric emptying, which can reduce postprandial glucose spikes after meals.
• May contribute to weight loss and reduced appetite in many patients with type 2 diabetes, which can further support metabolic health.

Warnings & Contraindications:

• For use only in adults with type 2 diabetes mellitus and only under the supervision of a healthcare professional.
• Contraindicated in patients with a known hypersensitivity to semaglutide or any component of the formulation.
• Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Use with caution in patients with a history of pancreatitis; discontinue and seek medical attention if severe abdominal pain occurs.
• Thyroid C-cell tumors: GLP-1 receptor agonists have been associated with an increased risk of thyroid C-cell tumors in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2) should discuss risks with their doctor before use.
• May cause dehydration due to gastrointestinal side effects (nausea, vomiting, diarrhea); ensure adequate fluid intake.
• May increase the risk of hypoglycemia when used with insulin or sulfonylureas; dose adjustment of concomitant therapies may be required.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Semaglutide is generally not recommended during pregnancy; your doctor may switch you to an alternative treatment.
• Inform your doctor about all medications you are taking, including insulin, oral antidiabetics, blood pressure medicines, and others, to avoid interactions.
• Not intended to diagnose, treat, cure, or prevent any disease beyond the approved indications for type 2 diabetes management.
• Keep out of reach of children.

Side Effects:

• Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, dyspepsia (indigestion), and fatigue. These are often mild to moderate and may decrease over time.
• Less common side effects: injection site reactions (redness, itching, swelling), headache, dizziness, and mild increase in heart rate.
• Serious side effects (seek immediate medical attention): signs of pancreatitis (severe, persistent abdominal pain that may radiate to the back, with or without vomiting), signs of allergic reaction (rash, itching, swelling of face/lips/tongue, difficulty breathing), symptoms of thyroid problems (neck mass, hoarseness, difficulty swallowing, shortness of breath), or severe dehydration.
• Hypoglycemia (low blood sugar) is more likely when Ozempic is used with insulin or sulfonylureas; symptoms include sweating, shakiness, confusion, fast heartbeat, and blurred vision. Treat promptly and contact your doctor if episodes are frequent or severe.

Storage Instructions:

Store in a refrigerator at 2–8°c before first use, protected from light. Do not freeze; discard if frozen. After first use, storage conditions and in-use shelf life should follow the official package leaflet (typically may be stored at room temperature below a specified limit or in a refrigerator for a limited period). Keep the pen cap on when not in use. Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription antidiabetic medicine (GLP-1 receptor agonist).
• Form: Pre-filled injectable pen for subcutaneous use.
• Strength: 0.5 mg semaglutide per dose (full cartridge content and number of doses per pen are not specified in the provided data; refer to the official pack for exact volume and dose count).
• Intended use: Adult type 2 diabetes management as adjunct to diet and exercise.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.